Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation

Abstract Elevated thyroid stimulating hormone (TSH) is required when preparing for radioactive iodine therapy in patients with differentiated thyroid cancer. Recombinant human TSH (rhTSH: Thyrogen; Genzyme Corporation, Cambridge, MA) avoids hypothyroidism and has been commonly used in place of thyro...

Full description

Saved in:
Bibliographic Details
Published in:World journal of nuclear medicine 2020-01, Vol.19 (1), p.61-64
Main Authors: Lawhn-Heath, Courtney, Flavell, Robert, Chuang, Eunice, Liu, Chienying
Format: Article
Language:English
Subjects:
Biotechnology industries
Cancer
Cancer metastasis
Cancer patients
Care and treatment
Case Report
Dosimetry
FDA approval
Glycoproteins
Hormones
Hypothyroidism
Iodine
Lung cancer
Lymphatic system
Metastasis
Neck
Patients
Pituitary hormones
Radiotherapy
Surveillance
Therapy
Thyroid cancer
Thyroid diseases
Thyroid hormones
Thyrotropin
Ultrasonic imaging
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Elevated thyroid stimulating hormone (TSH) is required when preparing for radioactive iodine therapy in patients with differentiated thyroid cancer. Recombinant human TSH (rhTSH: Thyrogen; Genzyme Corporation, Cambridge, MA) avoids hypothyroidism and has been commonly used in place of thyroid hormone withdrawal (THW) in this process. We describe a 31-year-old woman with sclerosing variant of papillary thyroid cancer with multiple lymph node metastases and elevated postoperative thyroglobulin suggesting the presence of distant metastases, who was found to have miliary pulmonary metastases on the posttherapy I-131 scan after THW, but not visible on the post therapy scan after rhTSH preparation.
ISSN:1450-1147
1607-3312
DOI:10.4103/wjnm.WJNM_29_19